About EASEE®
The typical treatment methods for epilepsy are medications. Yet, many patients with epilepsy do not benefit sufficiently from anti-epileptic drugs. When a patient has further epileptic episodes despite treatment with two effective anti-epileptic agents for the respective type of seizure or epilepsy, specialists refer to this as ‘drug-resistant epilepsy’.
With EASEE® I have gained new freedoms. I can finally move forward and push my limits.
Focused cortical stimulation is a new world-first procedure that represents an innovative approach for treating epileptic seizures and favourably affecting the course of the disease for patients with inoperable forms of focal epilepsy. EASEE® imposes virtually no external limitations on your daily life. You can engage in sports, work and all leisure activities – and all of this is possible with EASEE® without having to give up the security provided by brain stimulation.
EASEE® Family
Epilepsy patients is refractory to therapy
- Simple, low-risk procedure
- The head bone remains unopened
- The stimulation can't be felt
- Not visible to others from the outside
- Everyday movements remain untroubled
The EASEE® system is appropriate for treating many people with focal epilepsies. Since September 15, 2022, the EASEE® system has been CE certified for adults with therapy-refractory focal epilepsies.
The following epilepsy centres already have experience using EASEE® or are familiar with the data from clinical studies, so you may consult with them to see whether EASEE® might be considered a possible treatment option in your case. Children and adolescents may be eligible to participate in a study to be launched in the autumn of 2022.
Technology
EASEE® sends electrical impulses to the location in the brain where the epileptic seizures originate. It stabilises the brain without touching it.
By means of a minor surgical procedure performed under general anaesthesia, the wafer-thin electrode pad is implanted under the skin of the scalp. During the same procedure, the pulse generator is implanted in the chest area and connected to the electrode pad with a cable.
Find center of excellence
A so-called Laplace electrode generates fields and current flows perpendicular to the electrode pad. In the EASEE® System, the external ring-shaped electrode is replaced by four individual electrodes in order to adapt the direction of the resultant electrical field to spatially varying resistances. In this way, significant current flows can be achieved on the surface of the brain as well as a penetration depth comparable to that of more invasive procedures.
- Effective seizure control
- High-frequency pulses to interrupt emerging seizures
- DC-like pulses for neuromodulation
- Electrodes not visible from the outside
Our studies
The EASEE® system was tested for safety and effectiveness in adult patients with focal epilepsy in several European study centers. Two of the clinical studies, started in 2019 and 2020, are still ongoing to continuously document long-term effects. However, no more patients can be admitted because the recruitment phase has already been completed. Results and data from the clinical studies are published.
Anja Resler, responsible for clinical affairs, talks about the positive effects of EASEE in clinical studies
Following the positive clinical results in studies of the EASEE® System in adults, the Precisis team, in collaboration with five paediatric neurology centres in Germany, is planning a clinical study for children and adolescents. Listed in what follows, you will find the names of the participating epilepsy centres. If your child has treatment-resistant focal epilepsy and is 12 years of age or older, you may consider a professional consultation to determine whether your child is eligible to enrol in the study.
The EASEE® System is appropriate for people with focal epilepsy in whom medications are no longer effective or not sufficiently effective. Since September 15, 2022, the EASEE® system has been CE certified for adults with therapy-refractory focal epilepsies and is prescribed by neurologists/epileptologists.
The effects of EASEE®
In the adjoining figure, each bar represents one patient in the EASEE II and PIMIDES I studies. All bars that point to the left reflect a reduction in seizures. The four patients at the bottom experienced 100% seizure reduction; that is, they are now seizure-free. The upper bars that point to the right represent patients who did not benefit from EASEE®.
- 53% response rate (seizure reduction of at least 50%)
- Very good tolerability
- Stimulation is imperceptible
- Electrodes are not externally visible
- A median reduction of seizures of 52% after 6 months
- The effect becomes greater over time
- Four patients are consistently seizure-free
Precisis GmbH
Precisis is a private medical technology company devoted to improving the lives of patients with brain disorders through innovative technology.
The Precisis team develops novel bioelectronic treatment methods based on directing therapeutic currents to limited target areas of the brain. Based upon the unique needs of each patient, specific brain cells may thereby be activated or inhibited.
More information about us
